Patents by Inventor Volker Nolle
Volker Nolle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
REVERSIBLE CELL DETECTION VIA MHC WITH CONJUGATES HAVING AN ENZYMATICALLY CLEAVABLE DETECTION MOIETY
Publication number: 20230013963Abstract: The invention is directed to a Conjugate for labelling a target moiety on a cell, characterized by general formula (II): Xo-P-Ym, with Y: MHC-complex targeting TCR molecules, P: enzymatically degradable spacer, X: detection moiety, o: integer between 5 and 25, m: integer between 2 and 1000, wherein X and P; P and Y are covalently bound to each other and Y is bound to P via the C-terminus.Type: ApplicationFiled: December 9, 2020Publication date: January 19, 2023Applicant: Miltenyi Biotec B.V. & Co. KGInventors: Jennifer PANKRATZ, Jennifer BRIEDEN, Cesar EVARISTO, Volker NOLLE, Marek WIECZOREK -
Publication number: 20210301273Abstract: The present invention provides a composition comprising an isolated polypeptide having non-specific nuclease (NSN) activity for degrading nucleic acids comprising or consisting of at least 70% amino acid sequence identity to SEQ ID NO:2, wherein said polypeptide has NSN activity in a solution of about 4° C., and a cation complexing agent such as EDTA. Said composition may have preferentially a neutral to basic pH. A kit comprising said composition and a method using said composition are also disclosed.Type: ApplicationFiled: July 26, 2019Publication date: September 30, 2021Inventors: Skander Elleuche, Sarah Schmitz, Stefan Miltenyi, Volker Nolle
-
Patent number: 10871490Abstract: The invention is directed to a detection reagent for CAR expressing cells according to general formula (1) Xn—Sm—Do wherein X is a polypeptide comprising at least 20 amino acids of which at least two amino acids are connected by at least one disulfide group S is a spacer comprising at least 15 carbon atoms D is a detection moiety m, o are integers independently between 1 and 200 n is an integer between 4 and 200 with the provisio that X binds to the antigen binding domain of a chimeric antigen receptor of a cell. The detection agent can be used in a method to detect cells having an antigen binding domain of a chimeric antigen receptor (CAR) binding the detection reagent and preferable to remove the detection moiety D from the detected cell.Type: GrantFiled: January 27, 2017Date of Patent: December 22, 2020Assignee: Multenyi Biotec, gmbHInventors: Anne Richter, Michaela Niemoller, Volker Nolle, Stefan Miltenyi, Mario Assenmacher
-
Patent number: 10336799Abstract: The present invention provides FGF-2 polypeptides that differ from the wild-type FGF-2 (SEQ ID NO:1) at least at amino acid position 56, 102 and 119, wherein the differences are Q56I, N102G, K119N substitutions, leading to FGF-2 polypeptides with higher thermostability, higher biological activity and higher resistance to proteolytic degradation. These polypeptides can be used in cell culture media.Type: GrantFiled: April 6, 2015Date of Patent: July 2, 2019Assignee: Miltenyi Biotec GmbHInventor: Volker Nolle
-
Publication number: 20180217151Abstract: The present invention provides a method for reversible labeling an antigen A of a biological specimen comprising said antigen A with a monovalent antigen binding molecule K comprising a binding site B for specifically binding said antigen A, the method comprising the steps a) contacting said biological specimen comprising said antigen A with said antigen binding molecule K, thereby generating a complex of A/K, b) removing the monovalent antigen binding molecule K that is not bound in said complex of A/K, wherein the equilibrium dissociation constant (KD) for the binding of said antigen A and said monovalent antigen binding molecule K has a value of equal or greater than 0.5E-08 M and wherein the dissociation rate constant (k(off)) of said binding has a value of equal or greater than 1E-03 sec-1. In some embodiments of the invention a multimerization component F for multimerization of monovalent antigen binding molecules (F/K complex) is included in the method, wherein said F/K complex can be disrupted.Type: ApplicationFiled: December 13, 2017Publication date: August 2, 2018Inventors: Volker NÖLLE, Jennifer PANKRATZ, Gritt GÜNTHER
-
Patent number: 10018541Abstract: The invention is directed to a process for sorting target cells and non-target cells from a sample by a cell sorting valve microfabricated on a surface of a silicon substrate, with microfabricated channels leading from the cell sorting valve, wherein the cell sorting valve separates the target particles from non-target material; a disposable cartridge containing a sample reservoir, a sort reservoir and a waste reservoir; wherein the sample is provided in a buffer comprising nuclease.Type: GrantFiled: March 5, 2015Date of Patent: July 10, 2018Assignee: Miltenyi Biotec, GmbHInventors: Stefan Miltenyi, Tanno Hübel, Volker Nolle
-
Publication number: 20180112000Abstract: The present invention provides a humanized antibody or fragment thereof specific for the antigen CD3, wherein said antibody or fragment thereof comprises a heavy chain variable domain comprising a CDR1 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. In addition, the present invention provides a method for polyclonal stimulation of T cells comprising contacting a population of T cells with said anti-CD3 antibody, optionally with an anti-CD28 antibody, wherein said anti-CD3 antibody and optionally said anti-CD28 antibody are linked to particles. Further said anti-CD3 antibody can be used for reversible tagging of cells.Type: ApplicationFiled: May 6, 2016Publication date: April 26, 2018Inventors: Volker NÖLLE, Holger THIE, Andrew KAISER
-
Publication number: 20170248594Abstract: The invention is directed to a detection reagent for CAR expressing cells according to general formula (1) Xn—Sm—Do wherein X is a polypeptide comprising at least 20 amino acids of which at least two amino acids are connected by at least one disulfide group S is a spacer comprising at least 15 carbon atoms D is a detection moiety m, o are integers independently between 1 and 200 n is an integer between 4 and 200 with the provisio that X binds to the antigen binding domain of a chimeric antigen receptor of a cell. The detection agent can be used in a method to detect cells having an antigen binding domain of a chimeric antigen receptor (CAR) binding the detection reagent and preferable to remove the detection moiety D from the detected cell.Type: ApplicationFiled: January 27, 2017Publication date: August 31, 2017Applicant: Miltenyi Biotec GmbHInventors: Anne Richter, Michaela Niemoller, Volker Nolle, Stefan Miltenyi, Mario Assenmacher
-
Patent number: 9701756Abstract: The present invention provides a humanized antibody or fragment thereof specific for the antigen CD45R0, wherein said antibody or fragment thereof comprises a humanized heavy chain variable domain comprising a CDR1 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a humanized light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. It is also provided the use of the present antibody or fragment thereof for enrichment or depletion of CD45R0-expressing cells from a sample comprising CD45R0-expressing cells.Type: GrantFiled: November 25, 2015Date of Patent: July 11, 2017Assignee: Miltenyi Biotec GmbHInventors: Holger Thie, Stefan Tomiuk, Iris Bürger, Volker Nolle
-
Publication number: 20170059458Abstract: The invention is directed to a process for sorting target cells and non-target cells from a sample by a cell sorting valve microfabricated on a surface of a silicon substrate, with microfabricated channels leading from the cell sorting valve, wherein the cell sorting valve separates the target particles from non-target material; a disposable cartridge containing a sample reservoir, a sort reservoir and a waste reservoir; wherein the sample is provided in a buffer comprising nuclease.Type: ApplicationFiled: March 5, 2015Publication date: March 2, 2017Applicant: Miltenyi Biotec GmbHInventors: Stefan MILTENYI, Tanno Hübel, Volker Nolle
-
Patent number: 9518131Abstract: The present invention provides for a method for generating a metal ion binding protein, the method comprising a) integrating the amino acid sequence DDD into CDR1 of a light chain variable region of an antibody or fragment thereof; and b) combining the sequence of step a) with a heavy chain variable region of an antibody or fragment thereof; and c) isolating the protein. Also provided is the use of metal ion binding proteins generated by the method of the present invention for isolation and purification of proteins and for the reversible labeling of a target molecule. Also provided is a metal ion binding anti-CD8 protein.Type: GrantFiled: April 1, 2014Date of Patent: December 13, 2016Assignee: Miltenyi Biotech GmbHInventors: Holger Thie, Kristina Reck, Volker Nolle
-
Publication number: 20160152733Abstract: The present invention provides a humanized antibody or fragment thereof specific for the antigen CD45R0, wherein said antibody or fragment thereof comprises a humanized heavy chain variable domain comprising a CDR1 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2, and a CDR3 region of SEQ ID NO:3, and a humanized light chain variable domain comprising a CDR1 region of SEQ ID NO:4, a CDR2 region of SEQ ID NO:5, and a CDR3 region of SEQ ID NO:6. It is also provided the use of the present antibody or fragment thereof for enrichment or depletion of CD45R0-expressing cells from a sample comprising CD45R0-expressing cells.Type: ApplicationFiled: November 25, 2015Publication date: June 2, 2016Inventors: Holger THIE, Stefan Tomiuk, Iris Bürger, Volker Nolle
-
Publication number: 20150284443Abstract: The present invention provides FGF-2 polypeptides that differ from the wild-type FGF-2 (SEQ ID NO:1) at least at amino acid position 56, 102 and 119, wherein the differences are Q56I, N102G, K119N substitutions, leading to FGF-2 polypeptides with higher thermostability, higher biological activity and higher resistance to proteolytic degradation. These polypeptides can be used in cell culture media.Type: ApplicationFiled: April 6, 2015Publication date: October 8, 2015Inventor: Volker NOLLE
-
Publication number: 20140296491Abstract: The present invention provides for a method for generating a metal ion binding protein, the method comprising a) integrating the amino acid sequence DDD into CDR1 of a light chain variable region of an antibody or fragment thereof; and b) combining the sequence of step a) with a heavy chain variable region of an antibody or fragment thereof; and c) isolating the protein. Also provided is the use of metal ion binding proteins generated by the method of the present invention for isolation and purification of proteins and for the reversible labeling of a target molecule. Also provided is a metal ion binding anti-CD8 protein.Type: ApplicationFiled: April 1, 2014Publication date: October 2, 2014Inventors: Holger THIE, Kristina Reck, Volker Nolle